Feed XCUR
XC

Exicure, Inc.

XCUR · NASDAQ

$1.25 +0.56% (+$0.01)
1M +6.96%
Market Cap $8.60M
P/E Ratio -
Div. Yield -
ROE 237.91%
Piotroski F-Score Weak
1/9
Valuation
0 /100
Expensive
P/B 8.81x
PEG N/A
P/S N/A
Growth
0 /100
Declining
Book val. growth 35.92%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A
Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor
ROE 237.91%
ROA 72.69%
Asset turnover 0.00x
Debt
48 /100
Moderate
Current ratio 0.56x
Int. coverage -8,917.00x
Debt/Equity 0.00x
Stability
1 /100
Unstable
EPS volatility 181.89%
Profitable years 0
Beta 3.62x

Το Bulios Scoring περιγράφει την ποιότητα και το ιστορικό μιας εταιρείας, όχι τη μελλοντική απόδοση. Ένα υψηλό σκορ δεν είναι σήμα αγοράς. Μάθετε περισσότερα

Ρωτήστε το StockBot για XCUR
Online

Σχετικά με την εταιρεία

Exicure, Inc. is a biopharmaceutical company focused on developing novel therapeutics based on the technology of therapeutic coding. Its main product platform is based on a technology called Spherical Nucleic Acid (SNA™), which enables the creation of three-dimensional structures of nucleic acids that have the potential to modulate gene expression. Exicure aims to utilize this technology to develop therapeutics for various indications, including oncological diseases, dermatological conditions, and neurological disorders. The company also engages in research and development of therapeutic vaccines based on SNA™ technology. Exicure collaborates with pharmaceutical companies and academic institutions on the development and commercialization of its products. Shares of Exicure, Inc. may be an interesting investment opportunity for investors following the pharmaceutical industry and biopharmaceutical research.

Δεν είναι ακόμη διαθέσιμο στη γλώσσα σας, επομένως το κείμενο είναι στα αγγλικά.

Sector

Healthcare

Industry

Biotechnology

CEO

Jungsoo Kim

Employees

1

Headquarters

Redwood City

Επερχόμενα γεγονότα

12 ΝΟΕ

Earnings

Upcoming earnings report

53d

Χρησιμοποιούμε απαραίτητα cookies για τη λειτουργία του ιστότοπου και προαιρετικά αναλυτικά cookies για τη μέτρηση της χρήσης. Δείτε την Πολιτική απορρήτου μας.